SynthesisFrontiers in immunology2022

Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.

Zhongwang Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.